TY - JOUR
T1 - New drugs for HIV and hepatitis C virus infections
T2 - A report from CROI 2011
AU - Temesgen, Zelalem
PY - 2011/6
Y1 - 2011/6
N2 - Presentations on new therapies for hepatitis C virus (HCV) generated the most excitement at CROI 2011. Two new, orally available, direct-acting antivirals, boceprevir and telaprevir, promise to usher in a new era of combination therapy for chronic HCV infection. The antiretroviral drug development pipeline continues to expand, albeit at a slower pace than in recent years.
AB - Presentations on new therapies for hepatitis C virus (HCV) generated the most excitement at CROI 2011. Two new, orally available, direct-acting antivirals, boceprevir and telaprevir, promise to usher in a new era of combination therapy for chronic HCV infection. The antiretroviral drug development pipeline continues to expand, albeit at a slower pace than in recent years.
UR - http://www.scopus.com/inward/record.url?scp=84952989810&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84952989810&partnerID=8YFLogxK
U2 - 10.1358/dof.2011.036.06.1653892
DO - 10.1358/dof.2011.036.06.1653892
M3 - Article
AN - SCOPUS:84952989810
SN - 0377-8282
VL - 36
SP - 485
EP - 490
JO - Drugs of the Future
JF - Drugs of the Future
IS - 6
ER -